What is the clinical evidence from this study?

Study design: Cohort. Population: Type 1 Diabetes Mellitus (n=166). Intervention: Positivity for ≥2 cardiac autoantibodies (AAbs) vs. Positivity for ≤1 cardiac AAb. Primary outcome: Cardiovascular events (composite of nonfatal myocardial infarction, stroke, cardiovascular death, heart failure, or coronary artery bypass grafting) (HR 16.1, 95% CI 3.0-88.2, p=0.001).

What does this research mean for the field?

Positivity for two or more cardiac autoantibodies in patients with type 1 diabetes is associated with a markedly increased long-term risk of cardiovascular events, suggesting an autoimmune mechanism for cardiovascular disease in this population. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

To determine whether chronic hyperglycemia induces cardiac autoimmunity in type 1 diabetes mellitus and whether cardiac autoantibodies predict long-term cardiovascular disease complications.

July 25, 2026CirculationOpen Access

Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus

Q: What are the key findings of this study?

Positivity for ≥2 cardiac autoantibodies was associated with a 16.1-fold increased risk of cardiovascular events over a 26-year median follow-up in patients with type 1 diabetes mellitus.

View Full Paper

Ask AI

Bookmark

Key result

Multiple cardiac autoantibodies linked to ~16-fold higher cardiovascular risk in type 1 diabetes.

HR 16.1
95% CI 3.0-88.2
P=0.001
n=166

Why the study?

Poor glycemic control increases cardiovascular disease risk in T1DM, but mechanisms specific to T1DM, such as whether chronic hyperglycemia-induced cardiac autoimmunity contributes to complications, remain unknown.

Does positivity for ≥2 cardiac autoantibodies increase the risk of cardiovascular events in patients with type 1 diabetes mellitus?

Key Points

To determine whether chronic hyperglycemia induces cardiac autoimmunity in type 1 diabetes mellitus and whether cardiac autoantibodies predict long-term cardiovascular disease complications.
Assessed coronary artery calcification at years 7–9 of EDIC, high-sensitivity C-reactive protein (hsCRP) at EDIC years 4–6, and composite CVD events over a 26-year median follow-up.
In type 1 diabetes, 46%, 22%, and 11% in the HbA1c ≥9.0% group tested positive for ≥1, ≥2, and ≥3 cardiac AAbs, compared with 2%, 1%, and 0% in the HbA1c ≤7.0% group (P<0.001); no such association was seen in type 2 diabetes.
Positivity for ≥2 cardiac AAbs conferred an increased risk of CVD events (4 of 6; hazard ratio, 16.1; 95% CI, 3.0–88.2) and detectable coronary artery calcification in multivariable analysis (13 of 31; odds ratio, 60.1; 95% CI, 8.8–410.0; P<0.001).
Participants with ≥2 AAbs exhibited significantly higher subsequent hsCRP levels than those with ≤1 AAb (median 6.0 mg/L vs. 1.4 mg/L; P=0.003).

Study Design

Type

Cohort (n=166)

Multicenter

Yes

Structured PICO

Does positivity for ≥2 cardiac autoantibodies increase the risk of cardiovascular events in patients with type 1 diabetes mellitus?

Population

166 young adults with type 1 diabetes mellitus, free of baseline cardiovascular and renal disease, followed for a median of 26 years to assess the relationship between glycemic control, cardiac autoimmunity, and cardiovascular events.

Exposure

Positivity for ≥2 cardiac autoantibodies (AAbs) during DCCT

Comparator

Positivity for ≤1 cardiac AAb

Outcome

Composite of nonfatal myocardial infarction, stroke, cardiovascular death, congestive heart failure, or coronary artery bypass grafting over a 26-year median follow-uphard clinical

Main Result

Hazard Ratio: 16.1 (95% CI 3–88.2)

p-value: p=0.001

Cardiac autoantibody positivity may serve as an early biomarker for long-term cardiovascular risk in patients with type 1 diabetes mellitus.

Limitations

Small number of CVD events
Exact timing of seroconversion could not be established
Marked HbA1c separation by design limits assessment of milder elevations
CD4+ T cell responses not measured
Primary CVD outcome was a composite of atherosclerotic events rather than cardiomyopathy

Discussion

No takes yet. Share an insight, caveat, or question.

Key expert perspectives

Captured external expert commentary on this paper, strongest first. Original sources are linked where available.

ML Myra LipesImmunobiology investigator, Joslin Diabetes Center, Harvard

“Her group has also shown that poor glycemic control in patients with type 1 diabetes — but not in those with type 2 diabetes — was associated with cardiac autoimmunity. An unexpected finding was the similar cardiac autoantibody levels in the patients with type 1 diabetes, who were young adult and without diabetes complications, and a heart failure cohort with Chagas' cardiomyopathy, which is thought to be caused by chronic inflammation of the heart muscle ('myocarditis'), raising the possibility of a subclinical autoimmune-associated myocardial dysfunction in type 1 diabetes”

Joslin Diabetes CenterNews Coverage

ML Myra LipesImmunobiology investigator, Joslin Diabetes Center, Harvard

“Heart failure in particular has recently been recognized as an important complication of type 1 with national register-based studies showing tenfold increased risk of heart failure in individuals with poor glycemic control. In addition, there's a higher case fatality rate in type 1 than type 2 diabetes, which suggests different mechanisms for heart failure might be involved in type 1 diabetes.”

Joslin Diabetes CenterNews Coverage

Implication

May flag long-term cardiovascular risk in type 1 diabetes; hypothesis-generating and requires prospective validation before clinical use.

Cite This Study

Sousa et al. (2019) conducted a cohort in Type 1 Diabetes Mellitus (n=166). Positivity for ≥2 cardiac autoantibodies (AAbs) vs. Positivity for ≤1 cardiac AAb was evaluated on Cardiovascular events (composite of nonfatal myocardial infarction, stroke, cardiovascular death, heart failure, or coronary artery bypass grafting) (HR 16.1, 95% CI 3.0-88.2, p=0.001). Positivity for ≥2 cardiac autoantibodies was associated with a 16.1-fold increased risk of cardiovascular events over a 26-year median follow-up in patients with type 1 diabetes mellitus.

synapsesocial.com/papers/6a647f8e7ac8de810e7eb65c https://doi.org/10.1161/circulationaha.118.036068

View Full Paper

Ask AI

Bookmark

Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Key expert perspectives

Implication

Cite This Study

Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Key expert perspectives

Implication

Cite This Study

Also Consider

Also Consider